MLA
HALO icon

MB, Levis & Associates’s Halozyme HALO Stock Holding History

MB, Levis & Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-88
Closed -$5.04K – 298
2024
Q3 		$5.04K Buy
+88
New +$5.04K ﹤0.01% 222

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MB, Levis & Associates's HALO Position: Q4 2024 in Review

MB, Levis & Associates sold out of Halozyme (HALO) in Q4 2024, closing a stake of 88 shares — an estimated $5.04K sold.

MB, Levis & Associates first reported a position in HALO in Q3 2024 and held it in 1 quarter. The position peaked at $5.04K in Q3 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • MB, Levis & Associates reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • MB, Levis & Associates sold 88 Halozyme shares in Q4 2024, an estimated $5.04K.
  • MB, Levis & Associates first reported a position in Halozyme in Q3 2024 and held it in 1 quarter.
  • MB, Levis & Associates's Halozyme position peaked at $5.04K in Q3 2024.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on MB, Levis & Associates's 13F filing for Q4 2024, filed 7 May 2025.